Tharimmune, Inc. (THAR)
Automate Your Wheel Strategy on THAR
With Tiblio's Option Bot, you can configure your own wheel strategy including THAR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol THAR
- Rev/Share 0.0
- Book/Share -0.3167
- PB -4.8532
- Debt/Equity 0.0
- CurrentRatio 0.671
- ROIC 15.5071
- MktCap 4089005.0
- FreeCF/Share -4.1846
- PFCF -0.3798
- PE -0.3167
- Debt/Assets 0.0
- DivYield 0
- ROE -4.8932
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback
Published: May 06, 2025 by: Accesswire
Sentiment: Neutral
BRIDGEWATER, NEW JERSEY / ACCESS Newswire / May 6, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology released pharmacokinetic and metabolism data from its Phase 1 study of TH104, a buccal film formulation of nalmefene, in healthy subjects. Tharimmune recently highlighted the advancement of TH104 for the proposed indication of temporary prophylaxis against respiratory and/or central nervous system depression in military personnel and chemical incident responders exposed to high-potency opioids, following recent positive feedback from the U.S. Food and Drug Administration (FDA).
Read More
Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences
Published: May 01, 2025 by: Accesswire
Sentiment: Neutral
BRIDGEWATER, NJ / ACCESS Newswire / May 1, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology announced abstracts featuring clinical data on its lead drug candidate, TH104, have been accepted for presentation at the Digestive Disease Week (DDW) Annual Meeting and at the European Association for the Study of the Liver (EASL) International Liver Congress. Both conferences will take place in May 2025.
Read More
Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors
Published: April 30, 2025 by: Accesswire
Sentiment: Neutral
BRIDGEWATER, NJ / ACCESS Newswire / April 30, 2025 / Tharimmune, Inc., (NASDAQ:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, today announced the appointment of Clay Kahler and Gary Stetz to its Board of Directors, increasing the Tharimmune Board to nine Directors. As reported in a Form 8-K filed on April 25, 2025, Directors Leonard Mazur and Lynne Bui, M.D.
Read More
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
Published: March 24, 2025 by: Accesswire
Sentiment: Neutral
BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its novel oral antibody, TH023. In a murine model, a proprietary protease enzyme stabilized platform demonstrated successful delivery of infliximab, a tumor necrosis factor-alpha (TNF-α) inhibitor, in serum with concentrations detected being significantly higher than the standard serum trough concentration needed for antibody efficacy in immunology indications via injection (~3-5µg/ml).
Read More
About Tharimmune, Inc. (THAR)
- IPO Date 2022-01-12
- Website https://www.tharimmune.com
- Industry Biotechnology
- CEO Randy D. Milby MBA
- Employees 2